NEW YORK (GenomeWeb News) — Cenix BioScience will support Boehringer Ingelheim with RNAi-focused contract research services for its therapeutic drug programs under a new agreement, Cenix said today.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.